News
SAGA awarded €200,000 grant from Sweden’s innovation agency Vinnova
LUND, Sweden — /March 16, 2021/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, has been awarded a grant of 2.0 MSEK (~ €200,000) from the Swedish Governmental Agency for Innovation Systems (Vinnova) under the…
SAGA Diagnostics enters into Agreement with Alligator Bioscience in the phase 1b/2 OPTIMIZE-1 trial
LUND, Sweden — /February 25, 2021/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, has entered into a service agreement with Alligator Bioscience, a Swedish clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. SAGA…
SAGA enters collaboration with Institut Curie in the MONDRIAN trial
LUND, Sweden — /February 2, 2021/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, announced today its collaboration with the French comprehensive cancer center Institut Curie in the MONDRIAN breast cancer clinical trial. The…
SAGA Diagnostics announces CE-marking of SAGAsafe® EGFR T790M assay and hiring of two Sales Managers
LUND, Sweden — /October 20, 2020/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announced the CE IVD-marking of its SAGAsafe® EGFR T790M assay*. The assay is a digital PCR test run on…
SAGA Diagnostics and SensID collaborate on ultra-low allelic frequency control reagents for cancer mutations
ROSTOCK and LUND — /July 15, 2020/ — SensID GmbH, headquartered in Rostock, Germany, is a specialist for development and production of reference control materials for clinical genomics. SAGA Diagnostics AB, headquartered in Lund, Sweden, is a cancer genomics company focused on precision oncology and ultrasensitive liquid biopsy monitoring of cancer patients. Today…
SAGA enters into research collaboration with University College London
LUND, Sweden — /June 17, 2020/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announced a research collaboration with University College London (UCL) Cancer Institute. In the course of this collaboration, SAGA will design…
SAGA Diagnostics enters supply agreement with the German Institute for Hematopathology Hamburg
LUND, Sweden – /June 4, 2020/ – SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and ultrasensitive monitoring of cancer patients, today announces it has entered a supply agreement with the German Institute for Hematopathology Hamburg, a large private pathology based in Hamburg,…
SAGA represented in oral presentations at AACR and ASCO annual meetings and in a peer reviewed article
LUND, Sweden – /May 28, 2020/ – SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announces recent breast cancer research results recognized at leading international cancer research and oncology conferences, AACR and ASCO, and a leukemia…
SAGA expands with two diagnostics scientists to further accelerate launch of new products and services
LUND, Sweden — /March 30, 2020/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announces the appointment of two new team members to significantly strengthen SAGA’s R&D team: Sofia Birkeälv, PhD as Molecular Diagnostics Scientist, NGS Lead,…
SAGA Diagnostics extends its collaboration with Servier to use ultrasensitive SAGAsafe® technology in cancer clinical trials
LUND, Sweden – /January 28, 2020/ – SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announces it has entered service agreements with the international pharmaceutical company Servier, based in Paris, France. These deals exemplify the…